[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BIOTECHSCANNER Avatar @BIOTECHSCANNER BIOTECH SCANNER

BIOTECH SCANNER posts on X about $iova, $aqst, $arqt, market cap the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance XXXXX% stocks XXXXX% currencies XXXX%

Social topic influence $iova #1, $aqst #1, $arqt #1, market cap 5.26%, low market 5.26%, ceo 5.26%, health 5.26%, skin 5.26%, foam 5.26%, retirement XXXX%

Top accounts mentioned or mentioned by @salmonstockcar @iovancebio @chuck80339031 @mucosalmelanoma @therealdansfera @targetedonc @wangruntu1988 @credidarwi98272 @contrerass99659 @stocksdd @volstki @hensley1552 @mauriziobruno10 @darrenestes @dansfera

Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA) Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Viatris Inc (VTRS) GSK plc (GSK) AstraZeneca PLC (AZN) Sanofi (SNY) Synthetify (SNY)

Top Social Posts

Top posts by engagements in the last XX hours

"How to identify great biotech companies. Also my track record below. X. Undervalued (low market cap vs assets and market potential) X. Solid management (biotech experience CEO track record and reputation not too many turnovers) X. Great pipeline versus whats currently available (look for first and only or best in class potential. X. Solving a big unmet need X. Incremental successes through various stages of clinical trials X. Strong upcoming catalysts X. Positive interactions with FDA X. Buyout or partnership potential X. Similar compounds performing successfully on the market XX. Current"
X Link 2024-07-07T17:48Z 7610 followers, 200K engagements

"$AQST $IOVA - Good morning 🐉 family. You may have noticed that I have been very quiet lately and its intentional. First this is a very quiet period especially for $IOVA and $AQST. Second I have been very busy with a personal health scare related to my daughter. While vacationing in Vietnam this past summer she told us about a growth on her skin in near the area that she was too embarrassed to share. Because of that it kept growing to a large mole like growth. Now put yourself in my shoes especially what I have talked about here as it relates to possible skin cancer. This kinda tampered our"
X Link 2025-12-06T16:38Z 7610 followers, 5265 engagements

"$ARQT - I am so happy for shareholders. This has turned out to be one of the biggest calls that I made. I predicted in May of 2024 X months before Zoryve foam was approved for atopic dermatitis on July X 2024. The share price was about $XXXX in May of 2024 and today its $XXXXX. Zoryve approval is part of my 6-0 PDUFA record. Why was I so confident that Zoryve would be approved BECAUSE I HAVE WORKED WITH THE DRUG BEFORE. ZORYVE (roflumilast) belongs to the phosphodiesterase4 (PDE4) inhibitor class of drugs. Before being used to treat psoriasis roflumilast was used to treat COPD exacerbations"
X Link 2025-12-07T17:04Z 7610 followers, 4070 engagements

"$IOVA - My largest holding. Just chillin until 2026 arrives. Patience my friends. More DD will come soon"
X Link 2025-12-08T21:07Z 7610 followers, 2976 engagements

"$IOVA - I posted this before but worth noting that TIL therapy will be accepted and adopted as standard of care for many solid tumor cancers. UK approval for Amtagvi is probably next"
X Link 2025-11-03T01:24Z 7606 followers, 3334 engagements

"@Chuck80339031 $IOVA is a unicorn. 2026 and beyond will be very exciting starting in the 2H of 2026"
X Link 2025-12-07T15:31Z 7609 followers, 1056 engagements

"$IOVA $AQST - New head of CDER Dr. Richard Pazdur not even a month in his new role has announced his retirement. The FDAs craziness continues. Im not surprised though. Dr. Pazdur expressed concerns over the new Commissioner National Priority Review Voucher (CNPV)s legality weeks after his appointment. This was a shocker to me. I thought he would be on board with the program"
X Link 2025-12-03T14:10Z 7610 followers, 4921 engagements

"$AQST - One of the coolest things about investing in Aquestive Therapeutics is seeing how the pre-launch activities take shape. Being in the a part of multiple massive drug launches like Ozempic (Novo Nordisk) Jardiance + Spiriva (Boehringer Ingelheim) and Farxiga + Breztri (AstraZeneca) I can tell you that so far the pre-launch activities are very well executed so far. Remember Aquestive basically hired the Michael Jordan of ephedrine auto-injector sales and marketing expert in Sherry Korczynski who also brought her buddies from Mylan to work on market access as well. Sherry and her team"
X Link 2025-12-09T19:54Z 7610 followers, 1620 engagements

"$AQST $IOVA - This is a big surprise to me. I thought Dr. Richard Pazdur the new director of the Center for Drug Evaluation and Research (CDER) would be on board with the National Priority Voucher program. Apparently not"
X Link 2025-11-25T15:56Z 7610 followers, 6003 engagements

"$IOVA - Please correct the typo @IovanceBio and @TargetedOnc The OS rate should be X - year instead of 5-month. Cmon now In terms of survival the median overall survival (OS) for the overall population was XXXX months (95% CI 10.617.8) and the 5-month OS rate was 19.7%"
X Link 2025-11-26T17:10Z 7610 followers, 6246 engagements

"$AQST - $VTRS Viatris $GSK Glaxo Smith Kline and $AZN AstraZeneca $SNY Sanofi have massive footprints in the allergy and immunology space. These are the companies that could partner with $AQST or buy it outright. The advantage of partnering with one of these companies is that AQST doesnt have to find another partner for other markets around the world. They are already there AQST XXX the topic epinephrine gel for Alopecia Areata (AA) would look very attractive as an asset to these companies. I have said it before that AQST XXX could turn out to be even bigger than Anaphylm. The Adrenaverse"
X Link 2025-12-08T23:46Z 7610 followers, 1805 engagements

"$AQST $IOVA - Patience red days are loading opportunities"
X Link 2025-12-09T19:12Z 7610 followers, 1508 engagements

"On July X 2024 the share price of $ARQT was $XXXX. I predicted that it could hit $18-$25. I was wrong. It only got to $XXXXX on 12/31/2024. But today its at $XX. Maybe I know something about the pharmaceutical industry 😆. I have said that $AQST and $IOVA will both be in the teens levels. It will come"
X Link 2025-12-09T23:16Z 7610 followers, 3363 engagements